Home › All Companies › BEAM › Annual Report

Beam Therapeutics Inc. (BEAM) — Annual Report

AI-Powered SEC Filing Analysis

← All BEAM filings
Latest Annual Report Filed: 2026-02-24

Key Insights

  • Beam Therapeutics continued to invest heavily in research and development, with R&D expenses increasing significantly year-over-year.
  • The company expanded its collaboration with Pfizer and acquired Orbital Therapeutics, indicating continued growth and diversification of its pipeline.
  • Beam Therapeutics reported increased cash and cash equivalents, strengthening its financial position to support future operations and development.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Beam Therapeutics Inc.

Quarterly Report Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.